New article: Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China https://t.co/2U8UIurntC #lungcancer #oncology https://t.co/PvenkYPKV6
906 followers
18,959 followers
Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China: Purpose To evaluate the cost utility of camrelizumab plus… https://t.co/k0OWgicVkw #on
6,544 followers
New research: Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China: Purpose To evaluate the cost utility of camrelizumab plus… https://t.co